Published in APMIS on September 01, 2000
Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol (2001) 6.98
Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother (2004) 2.51
Characterization of phenotypic changes in Pseudomonas putida in response to surface-associated growth. J Bacteriol (2001) 2.33
Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother (2002) 1.85
Infection of orthopedic implants with emphasis on bacterial adhesion process and techniques used in studying bacterial-material interactions. Biomatter (2013) 1.72
Growing Burkholderia pseudomallei in biofilm stimulating conditions significantly induces antimicrobial resistance. PLoS One (2010) 1.13
Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother (2009) 1.02
Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis). J Clin Microbiol (2003) 1.01
High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2012) 0.95
A temporal examination of the planktonic and biofilm proteome of whole cell Pseudomonas aeruginosa PAO1 using quantitative mass spectrometry. Mol Cell Proteomics (2014) 0.81
Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet (1991) 3.37
Pathogenesis of cystic fibrosis. Lancet (1993) 3.34
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet (1991) 3.26
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol (1997) 3.23
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J (2000) 3.14
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand (1983) 3.13
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand (2007) 2.77
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol (1996) 2.55
N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (2001) 2.51
Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect (2001) 2.50
Validation of the Danish Birth Registration. J Clin Epidemiol (1996) 2.45
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother (1986) 2.43
Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand (1996) 2.42
Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest (1999) 2.24
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1991) 2.09
Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother (1990) 2.08
Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. J Clin Microbiol (1989) 2.07
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother (2000) 2.07
Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand (1981) 2.03
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother (1987) 2.00
A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med (1999) 1.99
Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax (1992) 1.97
Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J Antimicrob Chemother (2004) 1.96
[Guidelines on antibiotics in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.93
Cross-reactions between Legionella pneumophila (serogroup 1) and twenty-eight other bacterial species, including other members of the family Legionellaceae. Infect Immun (1983) 1.93
Epidemiology of Pseudomonas aeruginosa infection in patients treated at a cystic fibrosis centre. Acta Pathol Microbiol Scand B (1980) 1.90
The assessment of postoperative cognitive function. Acta Anaesthesiol Scand (2001) 1.90
Crossed immunoelectrophoretic analysis of Legionella pneumophila serogroup 1 antigens. Infect Immun (1983) 1.89
Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand (1997) 1.88
Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother (2000) 1.85
Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol (2000) 1.85
Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun (1990) 1.81
An antigen common to a wide range of bacteria. I. The isolation of a 'common antigen' from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.75
Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun (1983) 1.68
The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol (1986) 1.67
Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology (2000) 1.66
Immunological cross-reaction between antigen Tp-4 of Treponema pallidum and an antigen common to a wide range of bacteria. Acta Pathol Microbiol Immunol Scand B (1984) 1.60
Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis (1983) 1.56
Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol (1999) 1.54
Teenage girls and elderly women living in northern Europe have low winter vitamin D status. Eur J Clin Nutr (2005) 1.53
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun (1990) 1.51
Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol (1993) 1.51
Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol (1988) 1.50
Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol (1987) 1.49
Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol (1988) 1.46
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros (2008) 1.46
An antigen common to a wide range of bacteria. 2. A biochemical study of a "common antigen" from Pseudomonas aeruginosa. Acta Pathol Microbiol Scand B (1980) 1.45
Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol (1994) 1.43
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother (1987) 1.42
Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax (1992) 1.42
Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros (2009) 1.41
Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun (1985) 1.41
A ten year review of colomycin. Respir Med (2000) 1.40
[Guidelines for antibiotic use in the Laegeforeningens Medicinfortegnelse 2000]. Ugeskr Laeger (2001) 1.39
Dose-response relationship for mivacurium in patients with phenotypically abnormal plasma cholinesterase activity. Acta Anaesthesiol Scand (1995) 1.39
Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology (2001) 1.39
[Decreasing vaccination rate--increasing risk of epidemics]. Ugeskr Laeger (1996) 1.38
Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun (1984) 1.37
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS (2000) 1.33
Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis. Infect Immun (1983) 1.33
Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa. Eur J Biochem (1999) 1.30
[Treatment of upper respiratory tract infections?]. Ugeskr Laeger (2000) 1.29
Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiol Lett (2000) 1.28
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros (2011) 1.28
Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (1989) 1.28
Polyagglutinability due to loss of O-antigenic determinants in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand B (1985) 1.25
Half-life of plasma cholinesterase. Acta Anaesthesiol Scand (1988) 1.25
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand (1987) 1.24
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother (2001) 1.24
Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol (1998) 1.22
Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori. Clin Diagn Lab Immunol (1995) 1.22
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS (1994) 1.22
Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol (1999) 1.22
Studies on hypersensitivity to bacterial antigens in intrinsic asthma. Allergy (1982) 1.20
Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs (2001) 1.19
Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob Agents Chemother (1997) 1.19
Diagnosis and treatment of cystic fibrosis. Respiration (2000) 1.19
Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS (1993) 1.19
Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice. APMIS (1997) 1.19
Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect (1983) 1.18
Hypergammaglobulinemic purpura in cystic fibrosis. Acta Paediatr Scand (1978) 1.18
Intrinsic asthma and bacterial histamine release. Agents Actions (1982) 1.17
Antibody response in patients with Pseudomonas aeruginosa infection to a 'common antigen' from P. aeruginosa analysed by means of quantitative immunoelectrophoretic methods. Acta Pathol Microbiol Scand C (1980) 1.17
Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax (2009) 1.17
Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Infect Immun (1988) 1.17
Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J (2006) 1.17
Robbins device in biofilm research. Methods Enzymol (1999) 1.15
Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax (1994) 1.15
Genome fingerprinting as a typing method used on polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS (1991) 1.15
Quantitative immunoelectrophoretic analysis of Salmonella typhi antigens and of corresponding antibodies in human sera. Acta Pathol Microbiol Scand B (1980) 1.15
Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT. Acta Radiol (1997) 1.15
Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology (1985) 1.14
Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand (1982) 1.14
Sequence analysis of the Legionella micdadei groELS operon. FEMS Microbiol Lett (1991) 1.13
Antibacterial precipitins and autoantibodies in serum of patients with cystic fibrosis. Scand J Respir Dis (1975) 1.13